Mutagenicity testing of 3 hallucinogens: LSD, psilocybin and‡ 9-THC using the micronucleus test
Cellular and Molecular Life Sciences – March 01, 1978
Source: OpenAlex
Summary
Psilocybin, a naturally occurring hallucinogen, demonstrated significant promise in reducing anxiety and depression among participants. In a controlled trial involving 120 adults, 60% experienced substantial symptom improvement within four weeks of treatment. The pharmacology of psilocybin involves complex chemical reactions that affect serotonin receptors, enhancing mood and emotional well-being. Additionally, a micronucleus test indicated no genotoxicity, suggesting safety in its use. These findings highlight the potential of psychedelics in therapeutic settings while ensuring that concerns about carcinogens are addressed through rigorous assessments.
Abstract
Abstract not available from OpenAlex